{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "import math\n",
    "from flashtext import KeywordProcessor\n",
    "import datetime\n",
    "import pandas as pd\n",
    "from db_conn import get_connection\n",
    "import alchemy_con\n",
    "import spacy\n",
    "import en_core_web_sm\n",
    "# import nltk\n",
    "\n",
    "start_time = datetime.datetime.now()\n",
    "nlp = en_core_web_sm.load()\n",
    "# chunk_parser = nltk.RegexpParser('''NP: {<DT>?<JJ>*<NN>}''')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "engine = alchemy_con.get_engine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>sentence</th>\n",
       "      <th>table_id</th>\n",
       "      <th>drug</th>\n",
       "      <th>adverse_effect</th>\n",
       "      <th>frequency</th>\n",
       "      <th>table_title</th>\n",
       "      <th>foot_note</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2172021</td>\n",
       "      <td>Criterion ,  Randomized , STOP-Hypertension-2...</td>\n",
       "      <td>42838</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Entry Criteria as Met by Trials Comparing Cal...</td>\n",
       "      <td>trial acronyms are defined in the references</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2172027</td>\n",
       "      <td>Criterion ,  STOP-Hypertension-2 (Ref . 4 ) :...</td>\n",
       "      <td>42838</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Entry Criteria as Met by Trials Comparing Cal...</td>\n",
       "      <td>trial acronyms are defined in the references</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2172033</td>\n",
       "      <td>Criterion ,  Double-blinded or PROBE design P...</td>\n",
       "      <td>42838</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Entry Criteria as Met by Trials Comparing Cal...</td>\n",
       "      <td>trial acronyms are defined in the references</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2172039</td>\n",
       "      <td>Criterion ,  Double-blinded , STOP-Hypertensi...</td>\n",
       "      <td>42838</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Entry Criteria as Met by Trials Comparing Cal...</td>\n",
       "      <td>trial acronyms are defined in the references</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2172044</td>\n",
       "      <td>Criterion ,  Predefined clinical end points ;...</td>\n",
       "      <td>42838</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Entry Criteria as Met by Trials Comparing Cal...</td>\n",
       "      <td>trial acronyms are defined in the references</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        id                                           sentence  table_id  drug  \\\n",
       "0  2172021   Criterion ,  Randomized , STOP-Hypertension-2...     42838  None   \n",
       "1  2172027   Criterion ,  STOP-Hypertension-2 (Ref . 4 ) :...     42838  None   \n",
       "2  2172033   Criterion ,  Double-blinded or PROBE design P...     42838  None   \n",
       "3  2172039   Criterion ,  Double-blinded , STOP-Hypertensi...     42838  None   \n",
       "4  2172044   Criterion ,  Predefined clinical end points ;...     42838  None   \n",
       "\n",
       "  adverse_effect frequency                                        table_title  \\\n",
       "0           None      None   Entry Criteria as Met by Trials Comparing Cal...   \n",
       "1           None      None   Entry Criteria as Met by Trials Comparing Cal...   \n",
       "2           None      None   Entry Criteria as Met by Trials Comparing Cal...   \n",
       "3           None      None   Entry Criteria as Met by Trials Comparing Cal...   \n",
       "4           None      None   Entry Criteria as Met by Trials Comparing Cal...   \n",
       "\n",
       "                                        foot_note  \n",
       "0   trial acronyms are defined in the references   \n",
       "1   trial acronyms are defined in the references   \n",
       "2   trial acronyms are defined in the references   \n",
       "3   trial acronyms are defined in the references   \n",
       "4   trial acronyms are defined in the references   "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "hypers = pd.read_sql('select * from article_table_sentences_m where lower(sentence) like %(search_s)s', \\\n",
    "                     engine,\\\n",
    "                     params={'search_s':'%-hypertension%'})\n",
    "\n",
    "hypers.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "keyword_processor = KeywordProcessor(case_sensitive=False)\n",
    "words = ['hypertension'] #lower()\n",
    "for d in words:\n",
    "    keyword_processor.add_keyword(d.strip())\n",
    "    keyword_processor.add_keyword(' '+d.strip()+' ')\n",
    "    keyword_processor.add_keyword('-'+d.strip())\n",
    "    keyword_processor.add_keyword(d.strip()+'-')\n",
    "    keyword_processor.add_keyword('-'+d.strip()+'-')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Criterion ,  Randomized , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  STOP-Hypertension-2 (Ref . 4 ) : calcium channel blocker vs . diuretic or beta-blocker \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Double-blinded or PROBE design PROBE = Prospective , Randomized , Open , Blinded Endpoint evaluation design ; see test for details. , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Double-blinded , STOP-Hypertension-2 (Ref . 4 ) : PROBE \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Predefined clinical end points ; primary end points , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Total cardiovascular morbidity , STOP-Hypertension-2 (Ref . 4 ) : Stroke , myocardial infarction , all cardiovascular deaths \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Not short-acting calcium channel blocker ; specific drug used , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  nifedipine gastro-intestinal tract system , STOP-Hypertension-2 (Ref . 4 ) : diltiazem , initially short-acting \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Large trial (>1,000) , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Total number , STOP-Hypertension-2 (Ref . 4 ) : 6,614 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Duration ≥2 years , STOP-Hypertension-2 (Ref . 4 ) : +1 \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  (at least 3 years) , STOP-Hypertension-2 (Ref . 4 ) : (up to 5 years) \n",
      "['stop-hypertension-2']\n",
      " Criterion ,  Total points , STOP-Hypertension-2 (Ref . 4 ) : 6 \n",
      "['stop-hypertension-2']\n",
      " previous anti-hypertension therapy , All Patients (n = 1,717) : 32% \n",
      "['anti-hypertension']\n",
      " previous anti-hypertension therapy , No left ventricular hypertrophy (n = 1,411) : 30% \n",
      "['anti-hypertension']\n",
      " previous anti-hypertension therapy , left ventricular hypertrophy (n = 306) : 42% \n",
      "['anti-hypertension']\n",
      " previous anti-hypertension therapy , p Value : < 0.0001 \n",
      "['anti-hypertension']\n",
      " Pt No. ,  1 , Anti-hypertension Medications : beta-blocker \n",
      "['anti-hypertension']\n",
      " Pt No. ,  4 , Anti-hypertension Medications : angiotensin-converting enzyme inhibitor \n",
      "['anti-hypertension']\n",
      " Pt No. ,  5 , Anti-hypertension Medications : beta-blocker \n",
      "['anti-hypertension']\n",
      " Pt No. ,  6 , Anti-hypertension Medications : beta-blocker \n",
      "['anti-hypertension']\n",
      " Pt No. ,  9 , Anti-hypertension Medications : angiotensin-converting enzyme inhibitor , calcium channel blocker \n",
      "['anti-hypertension']\n",
      " Anti-hypertension medication , Premenopausal (+) CAD (n = 10) : 20% \n",
      "['anti-hypertension']\n",
      " Anti-hypertension medication , Postmenopausal (+) ERT , (+) CAD (n = 25) : 68% \n",
      "['anti-hypertension']\n",
      " Anti-hypertension medication , Postmenopausal (−) ERT , (+) CAD (n = 50) : 50% \n",
      "['anti-hypertension']\n",
      " Anti-hypertension medication , Male Control (n = 20) : 10% \n",
      "['anti-hypertension']\n",
      " Anti-hypertension medication , Male (+) CAD (n = 50) : 63% \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  BCAPS statin+beta-blocker , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  DAPHNE , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  ELSA , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  MIDAS , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  MITEC , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  Stanton et al. , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  STARR angiotensin-converting enzyme inhibitor , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Trial Name / First Author ,  VHAS , Treatment Category : Anti-hypertension \n",
      "['anti-hypertension']\n",
      " Medication use , Mean number of anti-hypertension , Low cardiorespiratory fitness (<85%) (n= 95) : 0.9 ± 1.1 \n",
      "['anti-hypertension']\n",
      " Medication use , Mean number of anti-hypertension , Adequate cardiorespiratory fitness (86% to 100%) (n= 134) : 0.7 ± 0.7 \n",
      "['anti-hypertension']\n",
      " Medication use , Mean number of anti-hypertension , High cardiorespiratory fitness (>100%) (n= 79) : 0.8 ± 0.9 \n",
      "['anti-hypertension']\n",
      " Medication use , Mean number of anti-hypertension , p Value : 0.19 \n",
      "['anti-hypertension']\n",
      " First Author , Year  (Ref.#) ,  Subclinical cardiovascular disease , Newman , 2001 (44) (Cardiovascular Health Study) , Main Outcome (s) for Frail vs . Nonfrail : Prevalent clinical CVD: 38% vs . 17% ; OR: 2.79 (95% CI: 2.12–3.67) Prevalent subclinical CVD: regional wall motion abnormality , left ventricular hypertrophy , pre-hypertension , low ankle-brachial index , carotid stenosis , silent cerebrovascular accident \n",
      "['pre-hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , n : 6,748 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , All-Cause Deaths : 2,531 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , All-Cause Age-Adjusted : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , All-Cause Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , All-Cause Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , cardiovascular disease Deaths The remainder of the cardiovascular disease deaths (n = 846 ; 25%) were chiefly myocardial degeneration with atherosclerosis (International Classification of Diseases Seventh Revision [ICD 7] code 422.1 ; n = 203) , other and unspecified diseases of heart (ICD 7 code 434 ; n = 167) , and aortic aneurysm (ICD 7 code 451 ; n = 105) . : 992 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , cardiovascular disease Age-Adjusted : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , cardiovascular disease Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal , cardiovascular disease Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.00 (ref) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , n : 9,577 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , All-Cause Deaths : 4,013 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , All-Cause Age-Adjusted : 1.04 (0.99–1.09) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , All-Cause Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.05 (0.99–1.11) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , All-Cause Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.03 (0.97–1.09) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , cardiovascular disease Deaths The remainder of the cardiovascular disease deaths (n = 846 ; 25%) were chiefly myocardial degeneration with atherosclerosis (International Classification of Diseases Seventh Revision [ICD 7] code 422.1 ; n = 203) , other and unspecified diseases of heart (ICD 7 code 434 ; n = 167) , and aortic aneurysm (ICD 7 code 451 ; n = 105) . : 1,384 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , cardiovascular disease Age-Adjusted : 1.12 (1.03–1.21) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , cardiovascular disease Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.13 (1.04–1.24) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-hypertensive , cardiovascular disease Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.09 (1.00–1.20) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , n : 2,176 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , All-Cause Deaths : 1,176 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , All-Cause Age-Adjusted : 1.12 (1.05–1.20) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , All-Cause Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.14 (1.06–1.24) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , All-Cause Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.09 (1.01–1.18) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , cardiovascular disease Deaths The remainder of the cardiovascular disease deaths (n = 846 ; 25%) were chiefly myocardial degeneration with atherosclerosis (International Classification of Diseases Seventh Revision [ICD 7] code 422.1 ; n = 203) , other and unspecified diseases of heart (ICD 7 code 434 ; n = 167) , and aortic aneurysm (ICD 7 code 451 ; n = 105) . : 530 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , cardiovascular disease Age-Adjusted : 1.27 (1.14–1.41) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , cardiovascular disease Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.28 (1.14–1.44) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 hypertension , cardiovascular disease Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.17 (1.04–1.31) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , n : 380 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , All-Cause Deaths : 252 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , All-Cause Age-Adjusted : 1.26 (1.11–1.44) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , All-Cause Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.28 (1.11–1.48) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , All-Cause Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.19 (1.03–1.37) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , cardiovascular disease Deaths The remainder of the cardiovascular disease deaths (n = 846 ; 25%) were chiefly myocardial degeneration with atherosclerosis (International Classification of Diseases Seventh Revision [ICD 7] code 422.1 ; n = 203) , other and unspecified diseases of heart (ICD 7 code 434 ; n = 167) , and aortic aneurysm (ICD 7 code 451 ; n = 105) . : 122 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , cardiovascular disease Age-Adjusted : 1.53 (1.27–1.85) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , cardiovascular disease Age- and University Covariate-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.51 (1.23–1.86) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120–139 / 80–89 mm Hg) , stage 1 hypertension (140–159 / 90–99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 hypertension , cardiovascular disease Age- , University Covariate- , and 62 / 66 Hypertension-Adjusted n = 15,488 due to missing body mass index , physical activity , and smoking status data; : 1.31 (1.06–1.61) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension', 'hypertension-adjusted']\n",
      " Age , yrs , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal (n = 6,748) : 18.3 ± 1.7 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Age , yrs , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-Hypertensive (n = 9,577) : 18.4 ± 1.8 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Age , yrs , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 Hypertension (n = 2,176) : 18.5 ± 2.0 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Age , yrs , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 Hypertension (n = 380) : 18.4 ± 1.8 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Age , yrs , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Total (N = 18,881) : 18.4 ± 1.8 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Systolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal (n = 6,748) : 108.6 ± 6.7 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Systolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-Hypertensive (n = 9,577) : 123.4 ± 7.2 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Systolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 Hypertension (n = 2,176) : 136.5 ± 11.0 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Systolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 Hypertension (n = 380) : 147.9 ± 17.1 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Systolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Total (N = 18,881) : 120.1 ± 12.7 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Diastolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal (n = 6,748) : 66.9 ± 6.8 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Diastolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-Hypertensive (n = 9,577) : 74.9 ± 7.6 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Diastolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 Hypertension (n = 2,176) : 83.1 ± 10.0 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Diastolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 Hypertension (n = 380) : 94.1 ± 16.3 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Diastolic blood pressure , mm Hg , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Total (N = 18,881) : 73.4 ± 9.9 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " BMI missing for 168 men . BMI , kg / m2 , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal (n = 6,748) : 21.4 ± 2.4 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " BMI missing for 168 men . BMI , kg / m2 , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-Hypertensive (n = 9,577) : 21.8 ± 2.5 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " BMI missing for 168 men . BMI , kg / m2 , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 Hypertension (n = 2,176) : 22.0 ± 2.7 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " BMI missing for 168 men . BMI , kg / m2 , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 Hypertension (n = 380) : 21.9 ± 2.9 \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " BMI missing for 168 men . BMI , kg / m2 , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Total (N = 18,881) : 21.7 ± 2.5 \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Physical activity information missing for 766 men . Physical activity &amp;amp;amp;amp;lt;1 h / week , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Normal (n = 6,748) : 2.4 (158) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Physical activity information missing for 766 men . Physical activity &amp;amp;amp;amp;lt;1 h / week , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Pre-Hypertensive (n = 9,577) : 3.4 (316) \n",
      "['pre-hypertension', 'hypertension', 'hypertension']\n",
      " Physical activity information missing for 766 men . Physical activity &amp;amp;amp;amp;lt;1 h / week , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 1 Hypertension (n = 2,176) : 3.5 (73) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n",
      " Physical activity information missing for 766 men . Physical activity &amp;amp;amp;amp;lt;1 h / week , University Entry JNC-7 Blood Pressure Category Current Joint National Committee on Prevention , Detection , Evaluation , and Treatment of High Blood Pressure (JNC-7) criteria categories: normotensive (&amp;amp;amp;amp;lt;120 / &amp;amp;amp;amp;lt;80 mm Hg) , pre-hypertension (120 to 139 / 80 to 89 mm Hg) , stage 1 hypertension (140 to 159 / 90 to 99 mm Hg) , and stage 2 hypertension (≥160 / ≥100 mm Hg) . Stage 2 Hypertension (n = 380) : 5.2 (19) \n",
      "['pre-hypertension', 'hypertension', 'hypertension', 'hypertension']\n"
     ]
    }
   ],
   "source": [
    "update_list = []\n",
    "for ind, row in hypers[:100].iterrows():\n",
    "    ori_found = []\n",
    "    sen = row['sentence']\n",
    "    print(sen)\n",
    "    found = keyword_processor.extract_keywords(sen.lower())\n",
    "    if len(found)>0:\n",
    "        _found = list(set(list(map(lambda x: x, found))))\n",
    "        sen_strs = sen.strip().lower().split(' ')\n",
    "#         doc = nlp(sen.strip().lower())\n",
    "#         tree= chunk_parser.parse(nltk.pos_tag(nltk.word_tokenize(sen.strip().lower())))\n",
    "#         for sub_tr in tree.subtrees():\n",
    "#             print(' '.join([le[0] for le in sub_tr.leaves()]))\n",
    "#         sen_strs = [c.text for c in doc.noun_chunks]\n",
    "#         print(sen_strs)\n",
    "        for f in _found:\n",
    "            ori_found.extend(list(filter(lambda x: x.find(f)>=0, sen_strs)))\n",
    "        print(ori_found)\n",
    "        update_list.append({'id':id, 'adverse_event':' '+' , '.join(list(set(ori_found)))+' '})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "'spacy.vocab.Vocab' object is not callable",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-20-085517aaff64>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvocab\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m: 'spacy.vocab.Vocab' object is not callable"
     ]
    }
   ],
   "source": [
    "doc.vocab()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
